Hongbo Ren

Hongbo Ren


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2023 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YMYi-Teng Meng
Yi-Teng Meng
YZYi Zhou
Yi Zhou
PHPei-Yu Han
Pei-Yu Han
HRHongbo Ren
Hongbo Ren
Ferroptosis inhibition attenuates inflammatory response in mice with acute hypertriglyceridemic pancreatitis

1 May 2024 in Pancreas
Verified
Journal Article
Closed access
YMYiteng Meng
Yiteng Meng
PHPeiyu Han
Peiyu Han
XMXiaoyu Ma
Xiaoyu Ma
YHYiting He
Yiting He
HCHetian Chen
Hetian Chen
HRHongbo Ren
Hongbo Ren
The incidence rate of hypertriglyceridemia pancreatitis (HTGP) has experienced a notable increase in recent years, with eclipsing alcohol as the second leading cause of acute pancreatitis (AP). HTGP is often associated with more severe local and systemic complications. Recognized as a metabolic disorder hypertriglyceridemia (HTG), it holds significant relevance in the pathogenesis of HTGP, yet its mechanisms are not fully understood. Both primary (genetic) and secondary (acquired) factors contribute to elevated triglyceride (TG) levels, which concurrently influence the progression of HTGP. This article presents a comprehensive review of the evolving research on HTGP pathogenesis, encompassing lipid synthesis and metabolism, calcium signal transduction, inflammatory mediators, endoplasmic reticulum stress, autophagy, mitochondrial injury by fatty acids, oxidative stress response, genetic factors, and gene mutations. By unraveling the intricate mechanisms underlying HTGP, this article aims to enhance physicians' understanding of the disease and facilitate the development of potential targeted pharmacological interventions for patients.

1 March 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
TXTianqi Xia
Tianqi Xia
FHFei Han
Fei Han
YWYaning Wang
Yaning Wang
XXXinyue Xie
Xinyue Xie
CYChenchen Yuan
Chenchen Yuan
YWYaodong Wang
Yaodong Wang
Background: The tetraspanin CD53 transmembrane protein is vital in immune cells like B cells and T cells, playing a crucial role in various inflammatory conditions. However, its involvement in neutrophils regarding inflammation remains uncertain. This study aims to examine the impact of CD53 on neutrophil extracellular traps (NETs) formation. Methods: Phorbol 12-myristate 13-acetate (PMA) was utilized to establish an in vitro classical NETs model to investigate the influence of CD53 on NETs formation and its regulatory mechanisms. Subsequently, the link between CD53 and acute pancreatitis (AP), a model of aseptic inflammatory responses connected to NETs, was verified. Peripheral blood neutrophils from clinical AP patients were collected to explore the role of CD53 in AP, while an AP mouse model induced by caerulein was employed to confirm the impact of CD53 inhibition on AP mice pancreatic tissue. Results: Our study has shown that CD53 is significantly elevated in in vitro NETs models and neutrophils from AP patients. The expression of CD53 is closely related to the clinical prognosis of AP patients. At the same time, CD53 neutralizing antibody (Anti-CD53) can significantly inhibit the formation of NETs in vitro, inflammatory injury in AP mice and the formation of NETs in damaged tissues. Mechanistically, CD53 can modulate the PI3K/AKT pathway and promote the formation of NETs. Finally, targeted regulation of CD53 can effectively reduce inflammatory injury and NETs formation in damaged tissues of AP mice. Conclusion: The results of this study mark the first confirmation that CD53 plays a crucial role in NETs formation. Targeting CD53 inhibition could potentially serve as a novel therapeutic approach for the treatment of AP.

14 February 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
YMYiteng Meng
Yiteng Meng
SSShuo Sha
Shuo Sha
JYJing Yang
Jing Yang
HRHongbo Ren
Hongbo Ren

8 July 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
PHPeiyu Han
Peiyu Han
HWHan Wang
Han Wang
YCYuyu Chen
Yuyu Chen
YGYuqiu Ge
Yuqiu Ge
HXHuiting Xu
Huiting Xu
YMYiteng Meng
Yiteng Meng
Liver cancer, the advanced stage of various chronic liver diseases, has garnered attention due to its high incidence and insidious progression. Lipid droplets (LDs), unique lipid storage organelles in hepatocytes, play a pivotal role in lipid metabolism. Lipophagy, a selective autophagy process initially identified in hepatocytes, regulates lipid homeostasis by selectively degrading LDs. This process offers a novel therapeutic avenue for addressing lipid metabolism disorders in liver cancer. This review highlights the regulatory role of lipophagy in liver cancer progression and its therapeutic potential. It elaborates on the molecular mechanisms underlying lipophagy-mediated LDs degradation and discusses the dual regulatory role of lipophagy in liver cancer. While lipophagy can suppress liver cancer development, under specific conditions, it may promote cancer cell proliferation, inhibit apoptosis, facilitate invasion and metastasis, and contribute to treatment resistance. Consequently, strategies targeting lipophagy for liver cancer prevention and therapy hold significant promise. These include interventions through traditional Chinese and Western medicine, as well as lifestyle modifications. This review evaluates current research, hotspots, and controversies in the field, aiming to provide innovative therapeutic strategies for liver cancer associated with abnormal lipid metabolism.